ValuEngine Upgrades Humana (NYSE:HUM) to “Buy”

Humana (NYSE:HUM) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Friday, ValuEngine reports.

Several other brokerages have also recently issued reports on HUM. Berenberg Bank reissued a “buy” rating on shares of Humana in a research report on Monday, October 21st. JPMorgan Chase & Co. increased their price target on shares of Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Morgan Stanley reduced their price target on shares of Humana from $342.00 to $337.00 and set an “overweight” rating on the stock in a research report on Thursday, September 26th. SunTrust Banks increased their price target on shares of Humana to $335.00 and gave the stock a “hold” rating in a research report on Thursday. They noted that the move was a valuation call. Finally, UBS Group increased their price target on shares of Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $322.63.

NYSE HUM traded up $2.44 during trading hours on Friday, reaching $317.58. The company had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The stock has a 50-day moving average of $277.48 and a 200 day moving average of $270.93. Humana has a 1-year low of $225.65 and a 1-year high of $342.03. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $39.82 billion, a P/E ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the Zacks’ consensus estimate of $4.58 by $0.45. Humana had a net margin of 4.13% and a return on equity of 22.47%. The company had revenue of $16.24 billion for the quarter, compared to analysts’ expectations of $16.15 billion. During the same quarter in the prior year, the company posted $4.58 earnings per share. Humana’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, sell-side analysts predict that Humana will post 17.75 EPS for the current year.

In related news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares in the company, valued at $3,764,361.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.54% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Advisors Inc. increased its stake in shares of Humana by 9.9% during the third quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock worth $99,000 after buying an additional 35 shares during the period. Lindbrook Capital LLC increased its stake in shares of Humana by 12.0% during the third quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock worth $84,000 after buying an additional 35 shares during the period. Regentatlantic Capital LLC increased its stake in shares of Humana by 0.4% during the second quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after buying an additional 42 shares during the period. Ballentine Partners LLC increased its stake in shares of Humana by 2.5% during the third quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock worth $448,000 after buying an additional 42 shares during the period. Finally, Cim Investment Mangement Inc. increased its stake in shares of Humana by 4.3% during the second quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after buying an additional 46 shares during the period. Hedge funds and other institutional investors own 92.93% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: Quiet Period Expirations Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.